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REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
Obstetrical and neonatal outcomes from the BEST Trial: single
embryo transfer with aneuploidy screening improves
outcomes after in vitro fertilization without compromising
delivery rates
Eric J. Forman, MD; Kathleen H. Hong, MD; Jason M. Franasiak, MD; Richard T. Scott Jr, MD
OBJECTIVE: We sought to determine whether performing elective transfer; P ¼ .6) through the fresh cycle and up to 1 frozen transfer,
single embryo transfer (eSET) after trophectoderm biopsy and rapid
aneuploidy screening results in improved obstetrical and neonatal
outcomes compared with transferring 2 untested embryos.
STUDY DESIGN: The Blastocyst Euploid Selective Transfer (BEST) Trial
enrolled infertile couples with a female partner up to age 42 years who
were undergoing in vitro fertilization. They were randomized to receive
transfer of a single euploid embryo (eSET) or to the standard of care
with transfer of 2 embryos that were not biopsied for aneuploidy
screening (untested 2-embryo transfer). Gestational age at delivery,
birthweight, and neonatal intensive care unit (NICU) lengths of stay
were compared with Mann-Whitney U. The risk of preterm delivery,
low birthweight, and NICU admission were compared with c2.
RESULTS: Among the 175 randomized patients, the delivery rates
were similar (69% after euploid eSET vs 72% after untested 2-embryoFrom Reproductive Medicine Associates of New Jersey, Basking Ridge, and
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.0001). The risk of preterm delivery (P ¼ .03), low birthweight (P ¼
.002), and NICU admission (P ¼ .04) were significantly higher after
untested 2-embryo transfer. Babies born after untested 2-embryo
transfer spent >5 times as many days in the NICU (479 vs 93 days;
P ¼ .03).
CONCLUSION: By enhancing embryo selection with a validated method
of aneuploidy screening, a single euploid embryo with high repro-
ductive potential can be selected for transfer. Using this approach,
eSET can be performed without compromising delivery rates and
improving the chance of having a healthy, term singleton delivery after
in vitro fertilization.
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fertilization (IVF) cycle,1 nearly half of all
US babies born after IVF are multiples.2
Despite improvements with in vitro cul-
ture systems, multiple embryo transfer
has remained the standard of care due tothe inability to predict the reproductive
potential of preimplantation embryos.
When selecting embryos by the same
criteria, it is mathematically impossible
that transferring 1 embryo can result in an
equal chance of delivery as transferring 2.
However, while multiple embryo transferthe Department of
Johnson Medical
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Congress of
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FEBRUARY 2014 Ameriimproves the chance for a delivery after
each IVF cycle, it carries a signiﬁcant risk
ofmultiple gestation conferring increased
maternal and neonatal morbidity. Al-
though many infertile couples initially
express a desire for twins, most would
prefer elective single embryo transfer
(eSET) if their chance for a delivery was
not compromised.3
To perform eSET without compro-
mising per-transfer delivery rates it will be
necessary to enhance the method of em-
bryo selection. Having a normal comple-
ment of 46 chromosomes is a necessary,
but not sufﬁcient, requirement for an
embryo to progress to a healthy newborn.
Early attempts using ﬂuorescence in situ
hybridization to predict the chromosomal
status of cleavage-stage embryos and
preferentially transfer those predicted to
be euploid were unable to improve de-
livery rates,4 likely due to a negative
impact of the biopsy5 at the cleavage stagecan Journal of Obstetrics& Gynecology 157.e1
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in this clinical setting.6 In recent years,
however, use of biopsy at the blastocyst
stage and more robust assays such as sin-
gle nucleotide polymorphism arrays and
real-time, quantitative polymerase chain
reaction (qPCR) to predict the karyotype
of embryos have been developed and have
demonstrated high accuracy in preclinical
validation,7,8 high negative predictive
value,9 and the ability to improve delivery
rates.10 The improvement in implantation
rates was of sufﬁcient magnitude to
demonstrate similar delivery rates after
transfer of a single euploid embryo
compared to transfer of 2 untested em-
bryos,11 something that had not previ-
ously been demonstrated in a randomized
controlled trial (RCT).12
Since virtually all deliveries after eSET
are singletons, we hypothesized that
obstetrical and neonatal outcomes would
be improved in the group randomized
to euploid eSET compared with those
receiving transfer of 2 untested embryos.
Given the enhanced embryo selection
afforded by combining embryo mor-
phology and ploidy status, this would
result in an improved chance for a term,
singleton delivery.
MATERIALS AND METHODS
The Blastocyst Euploid Selective Transfer
(BEST) Trial was an institutional review
boardeapproved (www.ClinicalTrials.
gov registration NCT01408433), ran-
domized, noninferiority trial comparing
single embryo transfer after real-time
qPCR-based comprehensive chromo-
some screening to transfer of 2 untested
embryos. Patients with an indication for
IVF who were <43 years old, with a
body mass index 30 kg/m2, and who
had an antiMüllerian hormone level of
1.2 ng/mL were eligible to participate
and informed consent was obtained.
Patients were randomized when at least 2
embryos reached the blastocyst stage of
development in a 1:1 allocation to
receive either euploid eSET or untested
2-embryo transfer. In the euploid eSET
group, embryos were tested with a rapid
qPCR method of detecting whole-
chromosome aneuploidy using assays
on each chromosome and providing a
result within 4 hours. Details of the rapid157.e2 American Journal of Obstetrics& GynecolqPCR screening methodology have been
previously described.7
Patients who had at least 2 expanded
blastocysts with a discrete inner cell mass
by day 5 were eligible for a fresh embryo
transfer in themorning on day 6. Those in
the euploid eSETgrouphad their embryos
biopsied in the afternoon of day 5 with
qPCR analysis run overnight. Patients
whose embryos were not blastocysts until
day 6 or who had contraindications to a
fresh transfer (risk of ovarian hyperstim-
ulation syndrome, thin endometrium,
premature progesterone elevation), had
all of their embryos cryopreserved on day
6 for a future frozen transfer. Those in the
euploid eSET group having a frozen
transfer had their embryos biopsied on
day 6 prior to cryopreservation.
The primary outcome of the study was
the ongoing pregnancy rate to a viable
gestation after the ﬁrst embryo transfer,
fresh or frozen. A summary of the results
has previously been published11 and the
ongoing pregnancy rate after euploid
eSET fell within the predetermined 20%
noninferiority margin. Patients who
received a fresh embryo transfer but did
not deliver were encouraged to have a
frozen transfer and remain in the group to
which they were initially randomized. The
current study is an analysis of the ﬁnal
obstetrical and neonatal delivery out-
comes through hospital discharge of pa-
tients randomized in the BEST Trial after
the initial fresh cycle and up to 1 frozen
transfer.
Data collection
In compliance with the Centers for Dis-
ease Control and Prevention standard of
practice for reporting IVF outcomes, pa-
tients were contacted after their expected
date of conﬁnement and were asked to
provide demographic data such as gesta-
tional age at delivery, mode of delivery,
birthweight, gender, and pregnancy
complications. Institutional review board
approval was obtained to perform a sur-
vey in which patients were queried in
more detail about their deliveries, in
particular howmany days their newborns
spent in the neonatal intensive care unit
(NICU). Medical records were obtained
and the lengths of stay and delivery out-
comes were veriﬁed. Deliveries occurredogy FEBRUARY 2014at a variety of different hospital settings,
both academic and community based,
and comparisons between speciﬁc rare
neonatal complications were not made.
Statistical analysis
Analysis was performed using the intent-
to-treat principle such that patients were
analyzed based on the group to which
they were randomized, regardless of how
many embryos were actually transferred.
The risk of preterm delivery (<37 weeks),
low birthweight (<2500 g), and NICU
admission were compared using c2. The
risk of very low birthweight (<1500 g), a
rare outcome, was compared with the
Fisher exact test. The birthweight, gesta-
tional age at delivery, and length of NICU
stay were compared using Mann-
Whitney U. A P value of < .05 was
considered statistically signiﬁcant.
RESULTS
In all, 175 patients were randomized, 89
to the euploid eSET group and 86 to the
untested 2-embryo transfer group. The 2
groups were similar in all demographic
characteristics with a mean age of 35.1
3.9 and 34.5  4.7 years (P ¼ .5),
respectively. Patients in each group pro-
duced a similar number of blastocysts
suitable for transfer with amean of 5.8
3.6 (range, 2e22) for euploid eSET and
5.3  3.0 (range, 2e18) for untested 2-
embryo transfer. In the euploid eSET
group 521 blastocysts were biopsied for
comprehensive chromosome screening
with an aneuploidy rate of 31% (162/
521). The proportion of aneuploid em-
bryos increased with increasing age
(21% for <35 years old, 34% for 35-37
years old, 56% for 38-40 years old, and
56% for 41-42 years old; P < .001). Two
patients in the euploid eSET group did
not have an embryo transfer as all of
their embryos were aneuploid. After the
fresh transfer, 34 patients who did not
conceive had frozen embryos available
and 30 have received subsequent frozen
embryo transfers (17 in the euploid eSET
group and 13 in the untested 2-embryo
transfer group). The cumulative de-
livery rate after up to 1 frozen transfer
was 69% (61/89) after euploid eSET and
72% (62/86) after untested 2-embryo
transfer (P ¼ .6) (Figure 1). In the
FIGURE 1
Study flow of participants in BEST Trial through up to 1 frozen ET
Patients were randomized when they produced at least 2 blastocysts into 2 groups, comprehensive chromosome screening with euploid elective single
ET (eSET) or untested 2-ET. Randomization was stratified for patients who were having fresh or frozen transfer. Patients who did not deliver after their
fresh transfer were given opportunity to have additional frozen ET performed.
BEST, Blastocyst Euploid Selective Transfer; ET, embryo transfer.
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bryos were transferred in 104 transfers
compared with 195 embryos in 99 trans-
fers to the untested 2-embryo transfer
group. The proportion of transferred
embryos that resulted in a live birth was
higher after euploid eSET (58% vs 46%;
P ¼ .048), suggesting an improvement in
embryo selection.
The proportion of deliveries that were
multiples was dramatically different with
47% (29/62) in the 2-embryo transfer
group, including 1 triplet delivery, and
1.6% (1/61) in the euploid eSET group,with 1 dizygotic twin delivery after the
patient elected to transfer 2 euploid em-
bryos outside of the study protocol
(relative risk, 28.5; 95% conﬁdence in-
terval [CI], 4.01e202.9; P < .0001). Per
patient randomized, the chance of having
a term singleton delivery, the ideal
outcome of an IVF cycle, was 60% (53/
89) after euploid eSET, which was nearly
twice as high as after untested 2-embryo
transfer, 31% (27/86) (P < .001).
Owing to the difference in multiple
gestation, the risk of preterm delivery was
higher after untested 2-embryo transferFEBRUARY 2014 Americompared with euploid eSET (29% vs
13%; relative risk, 2.21; 95% CI,
1.04e4.70; P¼ .03). Overall, the untested
2-embryo transfer group delivered at an
earlier gestational age (median 38.3
weeks; 95% CI, 37.3e38.6 weeks) than
the euploid eSET group (median, 39.0
weeks; 95% CI, 38.9e39.3 weeks) (P <
.001). The birthweights were lower after
untested 2-embryo transfer (median,
2778 vs 3317 g; P < .0001). The risk of a
newborn being low birthweight (<2500
g) was reduced in the euploid eSET group
compared to the untested 2-embryocan Journal of Obstetrics& Gynecology 157.e3
FIGURE 2
Birthweights of newborns in each group
Each circle represents birthweight in grams of each newborn in untested 2-embryo transfer (ET) and
euploid elective single ET (eSET) groups. Risk of low birthweight (<2500 g) was significantly higher
after untested 2-ET (P ¼ .002) with trend toward higher risk of very low birthweight (<1500 g)
(P ¼ .08).
CI, confidence interval.
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92]; P ¼ .002). Newborns at very low
birthweight (<1500 g) are at the most
signiﬁcant risk of long-term morbidity.
While this is a rare outcome, there was a
trend toward a reduced risk as none of the
newborns after euploid eSET were very
low birthweight (0% [0/62] vs 7% [6/92];
P ¼ .08) (Figure 2).
The risk of having a delivery with a
newborn admitted to the NICU was
higher in the untested 2-embryo transfer
group (26% [16/62] vs 11% [7/61]; P ¼
.04). Furthermore, due to more pro-
longedNICUstays among preterm twins,
the babies born after untested 2-embryo
transfer spent 5 times as much total
time in theNICUcompared to those after
euploid eSET (479 vs 93 days; P ¼ .03)
(Figure 3). There were no signiﬁcant
differences in outcomes when analysis
was restricted to the singleton deliveries
from each group.
Interestingly, the risk of cesarean sec-
tion was high and not different between
the 2 groups (56% after euploid eSET
and 61% after 2-embryo transfer; P¼.6).
There was no difference in the rate of
birth defects; however, 1 newborn in the
euploid eSET group was diagnosed with
cri du chat (partial 5p deletion) syn-
drome after delivery.
COMMENT
The initial ongoing pregnancy rates from
the BEST Trial were previously published
and demonstrated that by improving
embryo selection using a validated
method of aneuploidy screening, such as
rapid qPCR, eSET can be performed
effectively andmaintain excellent delivery
rates.11 The data presented in this study
represent the ultimate delivery outcomes
after up to 1 frozen transfer for those who
did not deliver after the fresh cycle. These
obstetrical and neonatal outcomes, not
previously reported, demonstrate signif-
icant improvements in multiple obstetric
and neonatal metrics. The fact that
singleton IVF pregnancies are safer than
twin pregnancies is well established13; the
novel aspect of this study is that infertile
couples did not compromise their chance
for a successful cycle to achieve better
obstetrical outcomes. Furthermore, the
trial included patients up to age 42 years.157.e4 American Journal of Obstetrics& GynecolIn contrast, most other RCTs of eSET vs
2-embryo transfer were limited to young
patients and, even in that good-prognosis
population, eSET resulted in inferior de-
livery rates per transfer.12,14 Although
similar delivery rates have been shown
when 1 fresh and 1 frozen single embryo
transfer are compared to 1 fresh double-
embryo transfer,15 outside of the RCT
settingmany patients are likely to elect for
a frozen double-embryo transfer after a
failed fresh eSET. The ability to performogy FEBRUARY 2014extended culture and select a single blas-
tocyst, rather than a cleavage-stage em-
bryo, can improve selection for eSET,16
but cannot result in an equivalent de-
livery rate as transferring 2 blastocysts.
One small RCT comparing the transfer of
a single blastocyst to 2 blastocysts failed
to show a signiﬁcantly inferior outcome
after eSET17; however, that trial only
included 48 patients and the 95% CI of
the difference included the possibility
that eSETwas as much as 40% inferior to
FIGURE 3
Length of neonatal intensive care unit stay in each group
Each circle in figure represents total number of days spent in neonatal intensive care unit (NICU) for
each delivery from untested 2-embryo transfer (ET) and euploid elective single ET (eSET) groups. Risk
of NICU admission was higher after untested 2-ET (P¼ .04), and newborns in that group spent more
total time in NICU (479 vs 93 days; P ¼ .03).
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widely practiced in the United States,
there is a need to demonstrate improved
selection to the point that eSET can rival
the excellent outcomes achieved when
transferring 2 high-quality blastocysts.
One limitation of the BEST Trial was
that it included only patients with anormal ovarian reserve, a normal BMI,
and normal endometrial cavities. How-
ever, many infertility patients would meet
these inclusion criteria and this embryo
selection strategy could be applied to
many patients undergoing IVF. Addi-
tionally, patients meeting these ovarian
reserve criteria are the most likely to haveFEBRUARY 2014 Ameriat least 2 high-quality embryos to select
from and be candidates for eSET. The
strategy of extended culture with embryo
biopsy and qPCR-based genetic analysis
does require additional laboratory pro-
cedures with added cost to the IVF cycle.
The lack of insurance coverage for the
embryo biopsy and genetic testing has
been a factor limiting broader acceptance
of this screening approach. Although
embryo biopsy is an invasive procedure,
when performed on trophectoderm at the
blastocyst stage, this procedure does not
seem to diminish an embryo’s chance of
implanting and progressing to delivery.5
Thus, even patients with a favorable
prognosis stand to improve their chance of
delivering after eSET when the risk of
aneuploidy has been dramatically re-
duced. While the high twin rate suggests
that many patients would have delivered if
eSET were performed without compre-
hensive chromosome screening, some
patients would have had an aneuploid
embryo transferred and thus had a failed
transfer.
Furthermore, by empowering the abil-
ity to perform eSET even up to age 42
years, trophectoderm biopsy with com-
prehensive chromosome screening results
in improved obstetrical outcomes as evi-
denced by higher birthweights, lower rates
of preterm delivery, lower rates of NICU
admission, and shorter NICU stays if
admission is required. These differences
can likely be attributed to the difference in
risk of twins, as the obstetrical and
neonatal outcomes between singleton de-
liveries in both groups were similar. In
general twin pregnancies have a higher
risk of cesarean section than singletons,
but in the current trial there was no dif-
ference in the risk of operative delivery
between the groups. IVF singleton preg-
nancies may be at an increased risk of ce-
sarean section, perhaps due to different
obstetrical risks in this population.18
Further studies evaluating long-term pe-
diatric outcomes and the overall cost efﬁ-
cacy of this approach are underway.
The aneuploidy screening that was
used in this trial was developed to elim-
inate the risk of whole-chromosome
aneuploidy, the leading cause of failed
IVF cycles and clinical miscarriages.19,20
Using this approach to improve embryocan Journal of Obstetrics& Gynecology 157.e5
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compromising delivery rates. A recent
study showed that fetuses with normal
karyotypes have up to a 1.7% risk of pos-
sessing clinically relevant deletions or
duplication.21 No preimplantation assays
have been validated to detect sub-
chromosomal insertions or deletions and
do not screen for cri du chat (partial
5p deletion), which 1 newborn was diag-
nosed with postnatally. Future research
using higher resolution arrays or next-
generation sequencing may be able to
incorporate preimplantation screening for
clinically relevant insertions and deletions.
In summary, by culturing embryos to
the blastocyst stage, performing a tro-
phectoderm biopsy, and amplifying DNA
with qPCR assays on each chromosome,
a single euploid blastocyst with high
reproductive potential can be selected for
transfer. This paradigm eliminates the
risk of multizygotic multiple gestation
and increases the chance for a healthy,
term singleton delivery without requiring
patients to undergo an increased number
of failed cycles. The improved obstetrical
and neonatal outcomes suggest this
approach may become the standard of
care for infertile couples requiring IVF.-
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